Uncommon Therapeutics focuses on building drugs for rare diseases using cutting-edge technology.
Uncommon Therapeutics has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in March 2025.
Uncommon Therapeutics's investors include Y Combinator, Pioneer Fund.
Uncommon Therapeutics is headquartered in San Francisco, United States.
Uncommon Therapeutics focuses on building drugs for rare diseases using cutting-edge technology.
Uncommon Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Uncommon Therapeutics — Funding & Investors." VCBacked, March 1, 2025, https://www.vcbacked.co/company/uncommon-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Uncommon Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/uncommon-therapeutics
{{cite web |title=Uncommon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/uncommon-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated